Our research reveals an unrecognized mechanism and druggable lynchpin for the modulation of the pan-mutant-RAS pathway, proposing a new potential therapeutic approach for treating RAS-mutant cancers; moreover, an alternative metabolism-regulating function of NPPS in glycolysis other than its canonical nucleotide-catalytic activity is demonstrated. This evidence concerns the gene ENPP1 and cancer.